Brought to you by 
Vantia Therapeutics gets £4mm through its Series B round
11 Aug 2011
Executive Summary
Vantia Therapeutics Ltd., a 2008 spin-off from Ferring Research Ltd. focused on gynecological/urological, oncology, and respiratory drug candidates, has raised £4mm ($6.5mm) through the closing of its Series B venture round. Novo AS and SV Life Sciences co-led the financing and were joined by MVM Life Science Partners and all returning shareholders. The funds will be used to continue developing Phase II candidates VA106483 for nocturia and VA111913 for dysmenorrhea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vantia Therapeutics gets £4mm through its Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice